UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies
UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies
Recruiting · NCT06743503 · Registry updated 2025-09-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies | Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, large B-cell lymphoma | Recruiting | Phase 1 | 2025-09-18 | NCT06743503 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Nanjing IASO Biotechnology Co., Ltd. | 14 |
| The First Affiliated Hospital with Nanjing Medical University | 319 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences | Tianjin | China | 2 |
| The First Affiliated Hospital of Nanjing Medical University | Nanjing | China | 21 |